Literature DB >> 22922215

The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.

Man-Tat Lau1, Peter C K Leung.   

Abstract

Insulin-like growth factor 1 (IGF1) is produced by ovarian cancer cells and it has been suggested that it plays an important role in tumor progression. In this study, we report that IGF1 treatment down-regulated E-cadherin by up-regulating E-cadherin transcriptional repressors, Snail and Slug, in human ovarian cancer cells. The pharmacological inhibition of phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) suggests that PI3K/Akt/mTOR signaling is required for IGF1-induced E-cadherin down-regulation. Moreover, IGF1 up-regulated Snail and Slug expression via the PI3K/Akt/mTOR signaling pathway. Finally, IGF1-induced cell proliferation was abolished by inhibiting PI3K/Akt/mTOR signaling. This study demonstrates a novel mechanism in which IGF1 down-regulates E-cadherin expression through the activation of PI3K/Akt/mTOR signaling and the up-regulation of Snail and Slug in human ovarian cancer cells.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922215     DOI: 10.1016/j.canlet.2012.08.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  54 in total

1.  Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations.

Authors:  Wei Zhang; Gang Chen; Jian-Gang Ren; Yi-Fang Zhao
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  IGF1 stimulates crypt expansion via differential activation of 2 intestinal stem cell populations.

Authors:  Laurianne Van Landeghem; M Agostina Santoro; Amanda T Mah; Adrienne E Krebs; Jeffrey J Dehmer; Kirk K McNaughton; Michael A Helmrath; Scott T Magness; P Kay Lund
Journal:  FASEB J       Date:  2015-04-02       Impact factor: 5.191

Review 3.  The links between insulin resistance, diabetes, and cancer.

Authors:  Etan Orgel; Steven D Mittelman
Journal:  Curr Diab Rep       Date:  2013-04       Impact factor: 4.810

4.  IGF-1 promotes angiogenesis in endothelial cells/adipose-derived stem cells co-culture system with activation of PI3K/Akt signal pathway.

Authors:  Shiyu Lin; Qi Zhang; Xiaoru Shao; Tao Zhang; Changyue Xue; Sirong Shi; Dan Zhao; Yunfeng Lin
Journal:  Cell Prolif       Date:  2017-09-27       Impact factor: 6.831

Review 5.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Authors:  G O'Callaghan; A Houston
Journal:  Br J Pharmacol       Date:  2015-10-26       Impact factor: 8.739

6.  MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.

Authors:  Yanyan Gu; Jonathan L Kaufman; Leon Bernal; Claire Torre; Shannon M Matulis; R Donald Harvey; Jing Chen; Shi-Yong Sun; Lawrence H Boise; Sagar Lonial
Journal:  Blood       Date:  2014-04-08       Impact factor: 22.113

Review 7.  Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.

Authors:  Seong Lin Teoh; Srijit Das
Journal:  Tumour Biol       Date:  2016-09-14

8.  Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.

Authors:  Cheng-Zhi Xu; Run-Jie Shi; Dong Chen; Yi-Yuan Sun; Qing-Wei Wu; Tao Wang; Pei-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

9.  Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways.

Authors:  Cemal Erdem; Alison M Nagle; Angelo J Casa; Beate C Litzenburger; Yu-Fen Wang; D Lansing Taylor; Adrian V Lee; Timothy R Lezon
Journal:  Mol Cell Proteomics       Date:  2016-06-30       Impact factor: 5.911

10.  GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma.

Authors:  Yuyan Chen; Qingqing Liu; Miaomiao Wu; Manhua Li; Haifang Ding; Xiaohang Shan; Jinxia Liu; Tao Tao; Runzhou Ni; Xudong Chen
Journal:  Tumour Biol       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.